<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39402013</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-5463</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>FEBS open bio</Title><ISOAbbreviation>FEBS Open Bio</ISOAbbreviation></Journal><ArticleTitle>Viral entry mechanisms: the role of molecular simulation in unlocking a key step in viral infections.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/2211-5463.13908</ELocationID><Abstract><AbstractText>Viral infections are a major global health concern, affecting millions of people each year. Viral entry is one of the crucial stages in the infection process, but its details remain elusive. Enveloped viruses are enclosed by a lipid membrane that protects their genetic material and these viruses are linked to various human illnesses, including influenza, and COVID-19. Due to the advancements made in the field of molecular simulation, significant progress has been made in unraveling the dynamic processes involved in viral entry of enveloped viruses. Simulation studies have provided deep insight into the function of the proteins responsible for attaching to the host receptors and promoting membrane fusion (fusion proteins), deciphering interactions between these proteins and receptors, and shedding light on the functional significance of key regions, such as the fusion peptide. These studies have already significantly contributed to our understanding of this critical aspect of viral infection and assisted the development of effective strategies to combat viral diseases and improve global health. This review focuses on the vital role of fusion proteins in facilitating the entry process of enveloped viruses and highlights the contributions of molecular simulation studies to uncover the molecular details underlying their mechanisms of action.</AbstractText><CopyrightInformation>© 2024 The Author(s). FEBS Open Bio published by John Wiley &amp; Sons Ltd on behalf of Federation of European Biochemical Societies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valério</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buga</LastName><ForeName>Carolina C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melo</LastName><ForeName>Manuel N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>Cláudio M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0003-1154-556X</Identifier><AffiliationInfo><Affiliation>Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lousa</LastName><ForeName>Diana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2309-0980</Identifier><AffiliationInfo><Affiliation>Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>101137419</GrantID><Agency>HORIZON EUROPE Framework Programme</Agency><Country /></Grant><Grant><GrantID>HR22-00722</GrantID><Agency>'la Caixa' Foundation</Agency><Country /></Grant><Grant><GrantID>2022.13959.BD</GrantID><Agency>Fundação para a Ciência e a Tecnologia</Agency><Country /></Grant><Grant><GrantID>LA/P/0087/2020</GrantID><Agency>Fundação para a Ciência e a Tecnologia</Agency><Country /></Grant><Grant><GrantID>SFRH/BD/148542/2019</GrantID><Agency>Fundação para a Ciência e a Tecnologia</Agency><Country /></Grant><Grant><GrantID>UIDB/04462/2020</GrantID><Agency>Fundação para a Ciência e a Tecnologia</Agency><Country /></Grant><Grant><GrantID>UIDP/04462/2020</GrantID><Agency>Fundação para a Ciência e a Tecnologia</Agency><Country /></Grant><Grant><GrantID>UIDB/04612/2020</GrantID><Agency>Fundação para a Ciência e a Tecnologia</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>FEBS Open Bio</MedlineTA><NlmUniqueID>101580716</NlmUniqueID><ISSNLinking>2211-5463</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">enveloped viruses</Keyword><Keyword MajorTopicYN="N">fusion peptide</Keyword><Keyword MajorTopicYN="N">membrane fusion</Keyword><Keyword MajorTopicYN="N">molecular simulation</Keyword><Keyword MajorTopicYN="N">receptor binding</Keyword><Keyword MajorTopicYN="N">viral entry</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>23</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39402013</ArticleId><ArticleId IdType="doi">10.1002/2211-5463.13908</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Zhang S‐Y, Jouanguy E, Sancho‐Shimizu V, von Bernuth H, Yang K, Abel L, Picard C, Puel A and Casanova J‐L (2007) Human toll‐like receptor‐dependent induction of interferons in protective immunity to viruses. Immunol Rev 220, 225–236.</Citation></Reference><Reference><Citation>Morens DM and Al E (2020) The COVID‐19 pandemic: what can we learn from it? J Clin Invest 130, 2140–2145.</Citation></Reference><Reference><Citation>Simons E, Ferrari M, Fricks J, Wannemuehler K, Anand A, Burton A and Strebel P (2012) Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet 379, 2173–2178.</Citation></Reference><Reference><Citation>Fields BN, Knipe DM, Howley PM and Griffin DE (2007) Fields' Virology. Lippincott Williams &amp; Wilkins.</Citation></Reference><Reference><Citation>Patel MM and Al E (2008) Global epidemiology of hepatitis a virus infection: new estimates of age‐specific antibody to HAV seroprevalence. Hepatology 48, 1333–1341.</Citation></Reference><Reference><Citation>Solomon T, Dung NM, Vaughn DW, Kneen R, Thao LT, Raengsakulrach B, Loan HT, Day NP, Farrar J, Myint KS et al. (2000) Neurological manifestations of dengue infection. Lancet 355, 1053–1059.</Citation></Reference><Reference><Citation>Clark A, Jit M, Warren‐Gash C, Guthrie B, Wang HHX, Mercer SW, Sanderson C, McKee M, Troeger C, Ong KL et al. (2020) Global, regional, and national estimates of the population at increased risk of severe COVID‐19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health 8, e1003–e1017.</Citation></Reference><Reference><Citation>UNICEF (2019) Progress on household drinking water, sanitation, and hygiene 2000–2017: Special focus on inequalities. UNICEF, New York, NY, USA.</Citation></Reference><Reference><Citation>Dimitrov DS (2004) Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2, 109–122.</Citation></Reference><Reference><Citation>Jones JE, Le Sage V and Lakdawala SS (2021) Viral and host heterogeneity and their effects on the viral life cycle. Nat Rev Microbiol 19, 272–282.</Citation></Reference><Reference><Citation>Maginnis MS (2018) Virus – receptor interactions: the key to cellular invasion. J Mol Biol 430, 2590–2611.</Citation></Reference><Reference><Citation>White JM and Whittaker GR (2016) Fusion of enveloped viruses in endosomes. Traffic 17, 593–614.</Citation></Reference><Reference><Citation>Benton DJ, Gamblin SJ, Rosenthal PB and Skehel JJ (2020) Structural transitions in influenza haemagglutinin at membrane fusion pH. Nature 583, 150–153.</Citation></Reference><Reference><Citation>Lipskij A, Arbeitman C, Rojas P, Ojeda‐May P and Garcia ME (2023) Dramatic differences between the structural susceptibility of the S1 pre‐ and S2 Postfusion states of the SARS‐CoV‐2 spike protein to external electric Fields revealed by molecular dynamics simulations. Viruses 15, 2405.</Citation></Reference><Reference><Citation>Yin H‐S, Wen X, Paterson RG, Lamb RA and Jardetzky TS (2006) Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439, 38–44.</Citation></Reference><Reference><Citation>Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A and Li F (2020) Structural basis of receptor recognition by SARS‐CoV‐2. Nature 581, 221–224.</Citation></Reference><Reference><Citation>Zhou T, Tsybovsky Y, Gorman J, Rapp M, Cerutti G, Chuang GY, Katsamba PS, Sampson JM, Schön A, Bimela J et al. (2020) Cryo‐EM structures of SARS‐CoV‐2 spike without and with ACE2 reveal a pH‐dependent switch to mediate endosomal positioning of receptor‐binding domains. Cell Host Microbe 28, 867–879.e5.</Citation></Reference><Reference><Citation>Dam K‐MA, Fan C, Yang Z and Bjorkman PJ (2024) Publisher correction: intermediate conformations of CD4‐bound HIV‐1 Env heterotrimers. Nature 626, E7.</Citation></Reference><Reference><Citation>Francis AC and Melikyan GB (2018) Live‐cell imaging of early steps of single HIV‐1 infection. Viruses 10, 275.</Citation></Reference><Reference><Citation>Bhagwat AR, Le Sage V, Nturibi E, Kulej K, Jones J, Guo M, Tae Kim E, Garcia BA, Weitzman MD, Shroff H et al. (2020) Quantitative live cell imaging reveals influenza virus manipulation of Rab11A transport through reduced dynein association. Nat Commun 11, 23.</Citation></Reference><Reference><Citation>Yokoyama M, Fujisaki S, Shirakura M, Watanabe S, Odagiri T, Ito K and Sato H (2017) Molecular dynamics simulation of the influenza a(H3N2) hemagglutinin trimer reveals the structural basis for adaptive evolution of the recent epidemic clade 3C.2a. Front Microbiol 8, 584.</Citation></Reference><Reference><Citation>Durrant JD, Kochanek SE, Casalino L, Ieong PU, Dommer AC and Amaro RE (2020) Mesoscale all‐atom influenza virus simulations suggest new substrate binding mechanism. ACS Cent Sci 6, 189–196.</Citation></Reference><Reference><Citation>Fujimoto K, Yamaguchi Y, Urano R, Shinoda W, Ishikawa T, Omagari K, Tanaka Y, Nakagawa A and Okazaki S (2021) All‐atom molecular dynamics study of hepatitis B virus containing pregenome RNA in solution. J Chem Phys 155, 145101.</Citation></Reference><Reference><Citation>Casalino L, Seitz C, Lederhofer J, Tsybovsky Y, Wilson IA, Kanekiyo M and Amaro RE (2022) Breathing and tilting: mesoscale simulations illuminate influenza glycoprotein vulnerabilities. ACS Cent Sci 8, 1646–1663.</Citation></Reference><Reference><Citation>Huber RG, Marzinek JK, Boon PLS, Yue W and Bond PJ (2021) Computational modelling of flavivirus dynamics: the ins and outs. Methods 185, 28–38.</Citation></Reference><Reference><Citation>Abduljalil JM, Elghareib AM, Samir A, Ezat AA and Elfiky AA (2023) How helpful were molecular dynamics simulations in shaping our understanding of SARS‐CoV‐2 spike protein dynamics? Int J Biol Macromol 242, 125153.</Citation></Reference><Reference><Citation>Dzimianski JV, Han J, Sautto GA, O'Rourke SM, Cruz JM, Pierce SR, Ecker JW, Carlock MA, Nagashima KA, Mousa JJ et al. (2023) Structural insights into the broad protection against H1 influenza viruses by a computationally optimized hemagglutinin vaccine. Communications Biology 6, 1–13.</Citation></Reference><Reference><Citation>Mercer J and Helenius A (2010) Virus entry by endocytosis. Annu Rev Biochem 79, 803–833.</Citation></Reference><Reference><Citation>Sieczkarski SB and Whittaker GR (2002) Influenza virus can enter and infect cells in the absence of clathrin‐mediated endocytosis. J Virol 76, 10455–10464.</Citation></Reference><Reference><Citation>Acosta EG and Bartenschlager R (2009) The multifaceted role of clathrin‐mediated endocytosis during viral infection. Trends Microbiol 17, 590–597.</Citation></Reference><Reference><Citation>Doherty GJ and McMahon HT (2009) Mechanisms of endocytosis. Annu Rev Biochem 78, 857–902.</Citation></Reference><Reference><Citation>White JM (1992) Membrane fusion. Science 258, 917–924.</Citation></Reference><Reference><Citation>Harrison SC (2008) Viral membrane fusion. Nat Struct Mol Biol 15, 690–698.</Citation></Reference><Reference><Citation>Belouzard S, Chu VC and Whittaker GR (2009) Entry route of the enveloped virus hepatitis C virus depends on clathrin‐mediated endocytosis. J Virol 83, 398–411.</Citation></Reference><Reference><Citation>Yuan M, Huang D, Lee C‐CD, Wu NC, Jackson AM, Zhu X, Liu H, Peng L, Van Gils MJ, Sanders RW et al. (2021) Structural and functional ramifications of antigenic drift in recent SARS‐CoV‐2 variants. Science 373, 818–823.</Citation></Reference><Reference><Citation>Miyauchi K, Kim Y, Latinovic O, Morozov V and Melikyan GB (2009) HIV enters cells via endocytosis and dynamin‐dependent fusion with endosomes. Cell 137, 433–444.</Citation></Reference><Reference><Citation>Grove J and Marsh M (2011) The cell biology of receptor‐mediated virus entry. J Cell Biol 195, 1071–1082.</Citation></Reference><Reference><Citation>Ivanovic T, Choi JL, Whelan SP, van Oijen AM and Harrison SC (2013) Influenza‐virus membrane fusion by cooperative fold‐back of stochastically induced hemagglutinin intermediates. eLife 2, e00333.</Citation></Reference><Reference><Citation>Cai Y, Zhang J, Xiao T, Peng H, Sterling SM, Walsh RM Jr, Rawson S, Rits‐Volloch S and Chen B (2020) Distinct conformational states of SARS‐CoV‐2 spike protein. Science 369, 1586–1592.</Citation></Reference><Reference><Citation>Chao LH, Klein DE, Schmidt AG, Peña JM and Harrison SC (2014) Sequential conformational rearrangements in flavivirus membrane fusion. eLife 3, e04389.</Citation></Reference><Reference><Citation>Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT and Veesler D (2020) Structure, function, and antigenicity of the SARS‐CoV‐2 spike glycoprotein. Cell 181, 281–292.e6.</Citation></Reference><Reference><Citation>White JM, Delos SE, Brecher M and Schornberg K (2008) Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol 43, 189–219.</Citation></Reference><Reference><Citation>Wyatt R and Sodroski J (1998) The HIV‐1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884–1888.</Citation></Reference><Reference><Citation>Kwong PD (2000) Structures of HIV‐1 gp120 envelope glycoproteins from laboratory‐adapted and primary isolates. Structure 8, 1329–1339.</Citation></Reference><Reference><Citation>Skehel JJ and Wiley DC (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69, 531–569.</Citation></Reference><Reference><Citation>Gamblin SJ and Skehel JJ (2010) Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 285, 28403–28409.</Citation></Reference><Reference><Citation>Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L et al. (2020) Structure of the SARS‐CoV‐2 spike receptor‐binding domain bound to the ACE2 receptor. Nature 581, 215–220.</Citation></Reference><Reference><Citation>Barton MI, MacGowan SA, Kutuzov MA, Dushek O, Barton GJ and van der Merwe PA (2021) Effects of common mutations in the SARS‐CoV‐2 spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. eLife 10, e70658.</Citation></Reference><Reference><Citation>Hasegawa K, Hu C, Nakamura T, Marks JD, Russell SJ and Peng K‐W (2007) Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol 81, 13149–13157.</Citation></Reference><Reference><Citation>Siebenmorgen T and Zacharias M (2020) Computational prediction of protein–protein binding affinities. Wiley Interdiscip Rev Comput Mol Sci 10, 1448.</Citation></Reference><Reference><Citation>Kumar V, Singh J, Hasnain SE and Sundar D (2021) Possible link between higher transmissibility of alpha, kappa and delta variants of SARS‐CoV‐2 and increased structural stability of its spike protein and hACE2 affinity. Int J Mol Sci 22, 9131.</Citation></Reference><Reference><Citation>Govind Kumar V, Polasa A, Agrawal S, Kumar TKS and Moradi M (2023) Binding affinity estimation from restrained umbrella sampling simulations. Nat Comput Sci 3, 59–70.</Citation></Reference><Reference><Citation>Yan R, Zhang Y, Li Y, Xia L, Guo Y and Zhou Q (2020) Structural basis for the recognition of SARS‐CoV‐2 by full‐length human ACE2. Science 367, 1444–1448.</Citation></Reference><Reference><Citation>Alenquer M, Ferreira F, Lousa D, Valério M, Medina‐Lopes M, Bergman ML, Gonçalves J, Demengeot J, Leite RB, Lilue J et al. (2021) Signatures in SARS‐CoV‐2 spike protein conferring escape to neutralizing antibodies. PLoS Pathog 17, e1009772.</Citation></Reference><Reference><Citation>Lupala CS, Li X, Lei J, Chen H, Qi J, Liu H and Su X‐D (2021) Computational simulations reveal the binding dynamics between human ACE2 and the receptor binding domain of SARS‐CoV‐2 spike protein. Quantitative Biology 9, 61.</Citation></Reference><Reference><Citation>Yan FF and Gao F (2021) Comparison of the binding characteristics of SARS‐CoV and SARS‐CoV‐2 RBDs to ACE2 at different temperatures by MD simulations. Brief Bioinform 22, 1122–1136.</Citation></Reference><Reference><Citation>Xu C, Wang Y, Liu C, Zhang C, Han W, Hong X, Wang Y, Hong Q, Wang S, Zhao Q et al. (2021) Conformational dynamics of SARS‐CoV‐2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo‐EM. Science Advances 7, eabe5575.</Citation></Reference><Reference><Citation>Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ et al. (2020) De novo design of picomolar SARS‐CoV‐2 miniprotein inhibitors. Science 370, 426–431.</Citation></Reference><Reference><Citation>Alexpandi R, De Mesquita JF, Pandian SK and Ravi AV (2020) Quinolines‐based SARS‐CoV‐2 3CLpro and RdRp inhibitors and spike‐RBD‐ACE2 inhibitor for drug‐repurposing against COVID‐19: an in silico analysis. Front Microbiol 11, 1796.</Citation></Reference><Reference><Citation>Awad IE, Abu‐Saleh AAAA, Sharma S, Yadav A and Poirier RA (2020) High‐throughput virtual screening of drug databanks for potential inhibitors of SARS‐CoV‐2 spike glycoprotein. J Biomol Struct Dyn 40, 2099–2112.</Citation></Reference><Reference><Citation>Padhi AK, Seal A, Khan JM, Ahamed M and Tripathi T (2021) Unraveling the mechanism of arbidol binding and inhibition of SARS‐CoV‐2: insights from atomistic simulations. Eur J Pharmacol 894, 173836.</Citation></Reference><Reference><Citation>Kumar V, Liu H and Wu C (2021) Drug repurposing against SARS‐CoV‐2 receptor binding domain using ensemble‐based virtual screening and molecular dynamics simulations. Comput Biol Med 135, 104634.</Citation></Reference><Reference><Citation>Wu K, Peng G, Wilken M, Geraghty RJ and Li F (2012) Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus. J Biol Chem 287, 8904–8911.</Citation></Reference><Reference><Citation>Jawad B, Adhikari P, Podgornik R and Ching W‐Y (2021) Key interacting residues between RBD of SARS‐CoV‐2 and ACE2 receptor: combination of molecular dynamics simulation and density functional calculation. J Chem Inf Model 61, 4425–4441.</Citation></Reference><Reference><Citation>Verma J and Subbarao N (2021) Insilico study on the effect of SARS‐CoV‐2 RBD hotspot mutants' interaction with ACE2 to understand the binding affinity and stability. Virology 561, 107–116.</Citation></Reference><Reference><Citation>Hsiao Y‐W, Bray DJ, Taddese T, Jiménez‐Serratos G and Crain J (2023) Structure adaptation in omicron SARS‐CoV‐2/hACE2: biophysical origins of evolutionary driving forces. Biophys J 122, 4057–4067.</Citation></Reference><Reference><Citation>Sergeeva AP, Katsamba PS, Liao J, Sampson JM, Bahna F, Mannepalli S, Morano NC, Shapiro L, Friesner RA and Honig B (2023) Free energy perturbation calculations of mutation effects on SARS‐CoV‐2 RBD::ACE2 binding affinity. J Mol Biol 435, 168187.</Citation></Reference><Reference><Citation>Gong Y, Qin S, Dai L and Tian Z (2021) The glycosylation in SARS‐CoV‐2 and its receptor ACE2. Signal Transduct Target Ther 6, 396.</Citation></Reference><Reference><Citation>Watanabe Y, Bowden TA, Wilson IA and Crispin M (2019) Exploitation of glycosylation in enveloped virus pathobiology. Biochimica et Biophysica Acta (BBA)‐General Subjects 1863, 1480–1497.</Citation></Reference><Reference><Citation>Watanabe Y, Berndsen ZT, Raghwani J, Seabright GE, Allen JD, Pybus OG, McLellan JS, Wilson IA, Bowden TA, Ward AB et al. (2020) Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Nat Commun 11, 2688.</Citation></Reference><Reference><Citation>Raman R, Tharakaraman K, Sasisekharan V and Sasisekharan R (2016) Glycan – protein interactions in viral pathogenesis. Curr Opin Struct Biol 40, 153–162.</Citation></Reference><Reference><Citation>Yang M, Huang J, Simon R, Wang L‐X and MacKerell AD Jr (2017) Conformational heterogeneity of the HIV envelope glycan shield. Sci Rep 7, 4435.</Citation></Reference><Reference><Citation>Crispin M, Ward AB and Wilson IA (2018) Structure and immune recognition of the HIV glycan shield. Annu Rev Biophys 47, 499–523.</Citation></Reference><Reference><Citation>Watanabe Y, Allen JD, Wrapp D, McLellan JS and Crispin M (2020) Site‐specific glycan analysis of the SARS‐CoV‐2 spike. Science 369, 330–333.</Citation></Reference><Reference><Citation>Sun X, Jayaraman A, Maniprasad P, Raman R, Houser KV, Pappas C, Zeng H, Sasisekharan R, Katz JM and Tumpey TM (2013) N‐linked glycosylation of the hemagglutinin protein influences virulence and antigenicity of the 1918 pandemic and seasonal H1N1 influenza a viruses. J Virol 87, 8756–8766.</Citation></Reference><Reference><Citation>Alymova IV, York IA, Air GM, Cipollo JF, Gulati S, Baranovich T, Kumar A, Zeng H, Gansebom S and McCullers JA (2016) Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulence. Sci Rep 6, 36216.</Citation></Reference><Reference><Citation>Wang C‐C, Chen J‐R, Tseng Y‐C, Hsu C‐H, Hung Y‐F, Chen S‐W, Chen C‐M, Khoo K‐H, Cheng T‐J, Cheng Y‐SE et al. (2009) Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci USA 106, 18137–18142.</Citation></Reference><Reference><Citation>Kasson PM and Pande VS (2008) Structural basis for influence of viral Glycans on ligand binding by influenza hemagglutinin. Biophys J 95, L48–L50.</Citation></Reference><Reference><Citation>Chen W, Sun S and Li Z (2012) Two glycosylation sites in H5N1 influenza virus hemagglutinin that affect binding preference by computer‐based analysis. PLoS One 7, e38794.</Citation></Reference><Reference><Citation>Tekin ED (2023) Investigation of the effects of N‐Acetylglucosamine on the stability of the spike protein in SARS‐CoV‐2 by molecular dynamics simulations. Computational and Theoretical Chemistry 1222, 114049.</Citation></Reference><Reference><Citation>Pandey VK, Sharma R, Prajapati GK, Mohanta TK and Mishra AK (2022) N‐glycosylation, a leading role in viral infection and immunity development. Mol Biol Rep 49, 8109–8120.</Citation></Reference><Reference><Citation>Singh JK, Singh J and Srivastava SK (2023) Investigating the role of glycans in omicron sub‐lineages XBB.1.5 and XBB.1.16 binding to host receptor using molecular dynamics and binding free energy calculations. J Comput Aided Mol Des 37, 551–563.</Citation></Reference><Reference><Citation>Maity S and Acharya A (2024) Many roles of carbohydrates: a computational spotlight on the coronavirus S protein binding. ACS Appl Bio Mater 7, 646–656.</Citation></Reference><Reference><Citation>Carbaugh DL and Lazear HM (2020) Flavivirus envelope protein glycosylation: impacts on viral infection and pathogenesis. J Virol 94, e00104.</Citation></Reference><Reference><Citation>Lan PD, Nissley DA, O'Brien EP, Nguyen TT and Li MS (2024) Deciphering the free energy landscapes of SARS‐CoV‐2 wild type and omicron variant interacting with human ACE2. J Chem Phys 160, 055101.</Citation></Reference><Reference><Citation>Re S and Mizuguchi K (2021) Glycan cluster shielding and antibody epitopes on Lassa virus envelop protein. J Phys Chem B 125, 2089–2097.</Citation></Reference><Reference><Citation>Seitz C, Deveci İ and McCammon JA (2023) Glycosylation and crowded membrane effects on influenza neuraminidase stability and dynamics. J Phys Chem Lett 14, 9926–9934.</Citation></Reference><Reference><Citation>Wood NT, Fadda E, Davis R, Grant OC, Martin JC, Woods RJ and Travers SA (2013) The influence of N‐linked glycans on the molecular dynamics of the HIV‐1 gp120 V3 loop. PLoS One 8, e80301.</Citation></Reference><Reference><Citation>Stewart‐Jones GBE, Soto C, Lemmin T, Chuang G‐Y, Druz A, Kong R, Thomas PV, Wagh K, Zhou T, Behrens A‐J et al. (2016) Trimeric HIV‐1‐Env structures define glycan shields from clades a, B, and G. Cell 165, 813–826.</Citation></Reference><Reference><Citation>Casalino L, Gaieb Z, Goldsmith JA, Hjorth CK, Dommer AC, Harbison AM, Fogarty CA, Barros EP, Taylor BC, Mclellan JS et al. (2020) Beyond shielding: the roles of glycans in the SARS‐CoV‐2 spike protein. ACS Central Science 6, 1722–1734.</Citation></Reference><Reference><Citation>Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C‐L, Abiona O, Graham BS and McLellan JS (2020) Cryo‐EM structure of the 2019‐nCoV spike in the prefusion conformation. Science 367, 1260–1263.</Citation></Reference><Reference><Citation>Yuan Y, Cao D, Zhang Y, Ma J, Qi J, Wang Q, Lu G, Wu Y, Yan J, Shi Y et al. (2017) Cryo‐EM structures of MERS‐CoV and SARS‐CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat Commun 8, 15092.</Citation></Reference><Reference><Citation>Gui M, Song W, Zhou H, Xu J, Chen S, Xiang Y and Wang X (2017) Cryo‐electron microscopy structures of the SARS‐CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res 27, 119–129.</Citation></Reference><Reference><Citation>Gur M, Taka E, Yilmaz SZ, Kilinc C, Aktas U and Golcuk M (2020) Conformational transition of SARS‐CoV‐2 spike glycoprotein between its closed and open states. J Chem Phys 153, 075101.</Citation></Reference><Reference><Citation>Valério M, Borges‐Araújo L, Melo MN, Lousa D and Soares CM (2022) SARS‐CoV‐2 variants impact RBD conformational dynamics and ACE2 accessibility. Frontiers in Medical Technology 4, 1009451.</Citation></Reference><Reference><Citation>Melikyan GB (2008) Common principles and intermediates of viral protein‐mediated fusion: the HIV‐1 paradigm. Retrovirology 5, 111.</Citation></Reference><Reference><Citation>Yao H and Hong M (2014) Conformation and lipid interaction of the fusion peptide of the paramyxovirus PIV5 in anionic and negative‐curvature membranes from solid‐state NMR. J Am Chem Soc 136, 2611–2624.</Citation></Reference><Reference><Citation>Donald JE, Zhang Y, Fiorin G, Carnevale V, Slochower DR, Gai F, Klein ML and DeGrado WF (2011) Transmembrane orientation and possible role of the fusogenic peptide from parainfluenza virus 5 (PIV5) in promoting fusion. Proc Natl Acad Sci 108, 3958–3963.</Citation></Reference><Reference><Citation>Suárez T, Gómara MJ, Goñi FM, Mingarro I, Muga A, Pérez‐Payá E and Nieva JL (2003) Calcium‐dependent conformational changes of membrane‐bound Ebola fusion peptide drive vesicle fusion. FEBS Lett 535, 23–28.</Citation></Reference><Reference><Citation>White SH and Wimley WC (1999) Membrane protein folding and stability: physical principles. Annu Rev Biophys Biomol Struct 28, 319–365.</Citation></Reference><Reference><Citation>Kielian M, Klimjack MR, Ghosh S and Duffus WA (1996) Mechanisms of mutations inhibiting fusion and infection by Semliki Forest virus. J Cell Biol 134, 863–872.</Citation></Reference><Reference><Citation>Lousa D, Pinto ART, Victor BL, Laio A, Veiga AS, Castanho MA and Soares CM (2016) Fusing simulation and experiment: the effect of mutations on the structure and activity of the influenza fusion peptide. Sci Rep 6, 1–14.</Citation></Reference><Reference><Citation>Yao H and Hong M (2013) Membrane‐dependent conformation, dynamics, and lipid interactions of the fusion peptide of the paramyxovirus PIV5 from solid‐state NMR. J Mol Biol 425, 563–576.</Citation></Reference><Reference><Citation>Lai AL, Moorthy AE, Li Y and Tamm LK (2012) Fusion activity of HIV gp41 fusion domain is related to its secondary structure and depth of membrane insertion in a cholesterol‐dependent fashion. J Mol Biol 418, 3–15.</Citation></Reference><Reference><Citation>Schaefer SL, Jung H and Hummer G (2021) Binding of SARS‐CoV‐2 fusion peptide to host endosome and plasma membrane. J Phys Chem B 125, 7732–7741.</Citation></Reference><Reference><Citation>Han X, Bushweller JH, Cafiso DS and Tamm LK (2001) Membrane structure and fusion‐triggering conformational change of the fusion domain from influenza hemagglutinin. Nat Struct Biol 8, 715–720.</Citation></Reference><Reference><Citation>Lorieau JL, Louis JM and Bax A (2010) The complete influenza hemagglutinin fusion domain adopts a tight helical hairpin arrangement at the lipid: water interface. Proc Natl Acad Sci 107, 11341–11346.</Citation></Reference><Reference><Citation>Cross KJ, Langley WA, Russell RJ, Skehel JJ and Steinhauer DA (2009) Composition and functions of the influenza fusion peptide. Protein Pept Lett 16, 766–778.</Citation></Reference><Reference><Citation>Huang Q, Chen C‐L and Herrmann A (2004) Bilayer conformation of fusion peptide of influenza virus hemagglutinin: a molecular dynamics simulation study. Biophys J 87, 14–22.</Citation></Reference><Reference><Citation>Li J, Das P and Zhou R (2010) Single mutation effects on conformational change and membrane deformation of influenza hemagglutinin fusion peptides. J Phys Chem B 114, 8799–8806.</Citation></Reference><Reference><Citation>Légaré S and Lagüe P (2012) The influenza fusion peptide adopts a flexible flat V conformation in membranes. Biophys J 102, 2270–2278.</Citation></Reference><Reference><Citation>Légaré S and Lagüe P (2014) The influenza fusion peptide promotes lipid polar head intrusion through hydrogen bonding with phosphates and N‐terminal membrane insertion depth. Proteins: Struct Funct Bioinf 82, 2118–2127.</Citation></Reference><Reference><Citation>Victor BL, Lousa D, Antunes JM and Soares CM (2015) Self‐assembly molecular dynamics simulations shed light into the interaction of the influenza fusion peptide with a membrane bilayer. J Chem Inf Model 55, 795–805.</Citation></Reference><Reference><Citation>Worch R, Filipek A, Krupa J, Szymaniec A and Setny P (2017) Three conserved residues of influenza fusion peptide alter its behavior at the membrane interface. Eur Biophys J Biophys Lett 233, 392.</Citation></Reference><Reference><Citation>Worch R, Dudek A, Krupa J, Szymaniec A and Setny P (2018) Charged N‐terminus of influenza fusion peptide facilitates membrane fusion. Int J Mol Sci 19, 578.</Citation></Reference><Reference><Citation>Larsson P and Kasson PM (2013) Lipid tail protrusion in simulations predicts fusogenic activity of influenza fusion peptide mutants and conformational models. PLoS Comput Biol 9, e1002950.</Citation></Reference><Reference><Citation>Zhang Y, Ghosh U, Xie L, Holmes D, Severin KG and Weliky DP (2023) Lipid acyl chain protrusion induced by the influenza virus hemagglutinin fusion peptide detected by NMR paramagnetic relaxation enhancement. Biophys Chem 299, 107028.</Citation></Reference><Reference><Citation>Kasson PM, Lindahl E and Pande VS (2010) Atomic‐resolution simulations predict a transition state for vesicle fusion defined by contact of a few lipid tails. PLoS Comput Biol 6, e1000829.</Citation></Reference><Reference><Citation>Valério M, Mendonça DA, Morais J, Buga CC, Cruz CH, Castanho MARB, Melo MN, Soares CM, Veiga AS and Lousa D (2022) Parainfluenza fusion peptide promotes membrane fusion by assembling into Oligomeric Porelike structures. ACS Chem Biol 17, 1831–1843.</Citation></Reference><Reference><Citation>Wang W, Tan J and Ye S (2020) Unsaturated lipid accelerates formation of Oligomeric β‐sheet structure of GP41 fusion peptide in model cell membrane. J Phys Chem B 124, 5169–5176.</Citation></Reference><Reference><Citation>Meher G, Sinha S, Pattnaik GP, Dastidar SG and Chakraborty H (2019) Cholesterol modulates membrane properties and the interaction of gp41 fusion peptide to promote membrane fusion. J Phys Chem B 33, 7113–7122.</Citation></Reference><Reference><Citation>Villalaín J (2022) Envelope E protein of dengue virus and phospholipid binding to the late endosomal membrane. Biochim Biophys Acta Biomembr 1864, 183889.</Citation></Reference><Reference><Citation>Campbell O and Monje‐Galvan V (2023) Lipid composition modulates interactions of p7 viroporin during membrane insertion. J Struct Biol 215, 108013.</Citation></Reference><Reference><Citation>Hao Y, Wu R, Wang F, Zhang L, Wang Z, Song X and Liu L (2022) Functional peptides from SARS‐CoV‐2 binding with cell membrane: from molecular dynamics simulations to cell demonstration. Cells 11, 1738.</Citation></Reference><Reference><Citation>Lynch DL, Pavlova A, Fan Z and Gumbart JC (2023) Understanding virus structure and dynamics through molecular simulations. J Chem Theory Comput 19, 3025–3036.</Citation></Reference><Reference><Citation>Soñora M, Barrera EE and Pantano S (2022) The stressed life of a lipid in the Zika virus membrane. Biochim Biophys Acta Biomembr 1864, 183804.</Citation></Reference><Reference><Citation>White JM, Ward AE, Odongo L and Tamm LK (2023) Viral membrane fusion: a dance between proteins and lipids. Annual Review of Virology 10, 139–161.</Citation></Reference><Reference><Citation>Van Doren SR, Scott BS and Koppisetti RK (2023) SARS‐CoV‐2 fusion peptide sculpting of a membrane with insertion of charged and polar groups. Structure 31, 1184–1199.e3.</Citation></Reference><Reference><Citation>Nilsson LB, Sun F, Kadupitiya JCS and Jadhao V (2023) Molecular dynamics simulations of deformable viral Capsomers. Viruses 15, 1672.</Citation></Reference><Reference><Citation>Rice A, Haldar S, Wang E, Blank PS, Akimov SA, Galimzyanov TR, Pastor RW and Zimmerberg J (2022) Planar aggregation of the influenza viral fusion peptide alters membrane structure and hydration, promoting poration. Nat Commun 13, 1–15.</Citation></Reference><Reference><Citation>Shen H and Wu Z (2022) Effect of disulfide bridge on the binding of SARS‐CoV‐2 fusion peptide to cell membrane: a coarse‐grained study. ACS Omega 7, 36762–36775.</Citation></Reference><Reference><Citation>Khelashvili G, Plante A, Doktorova M and Weinstein H (2021) Ca2+−dependent mechanism of membrane insertion and destabilization by the SARS‐CoV‐2 fusion peptide. Biophys J 120, 1105–1119.</Citation></Reference><Reference><Citation>Pabis A, Rawle RJ and Kasson PM (2020) Influenza hemagglutinin drives viral entry via two sequential intramembrane mechanisms. Proc Natl Acad Sci 117, 7200–7207.</Citation></Reference><Reference><Citation>Cross KJ, Wharton SA, Skehel JJ, Wiley DC and Steinhauer DA (2001) Studies on influenza haemagglutinin fusion peptide mutants generated by reverse genetics. EMBO J 20, 4432–4442.</Citation></Reference><Reference><Citation>Su R, Zeng J, Marcink TC, Porotto M, Moscona A and O'Shaughnessy B (2023) Host cell membrane capture by the SARS‐CoV‐2 spike protein fusion intermediate. ACS Cent Sci 9, 1213–1228.</Citation></Reference><Reference><Citation>Xu D and Zhang Y (2012) Ab initio protein structure assembly using continuous structure fragments and optimized knowledge‐based force field. Proteins: Struct Funct Bioinf 80, 1715–1735.</Citation></Reference><Reference><Citation>Hunt AC, Case JB, Park Y‐J, Cao L, Wu K, Walls AC, Liu Z, Bowen JE, Yeh H‐W, Saini S et al. (2022) Multivalent designed proteins neutralize SARS‐CoV‐2 variants of concern and confer protection against infection in mice. Sci Transl Med 14, eabn1252.</Citation></Reference><Reference><Citation>Humphrey W, Dalke A and Schulten K (1996) VMD: Visual molecular dynamics. J Mol Graph 14, 33–38.</Citation></Reference><Reference><Citation>Welch BD, Liu Y, Kors CA, Leser GP, Jardetzky TS and Lamb RA (2012) Structure of the cleavage‐activated prefusion form of the parainfluenza virus 5 fusion protein. Proc Natl Acad Sci 109, 16672–16677.</Citation></Reference><Reference><Citation>Lousa D and Soares CM (2021) Molecular mechanisms of the influenza fusion peptide: insights from experimental and simulation studies. FEBS Open Bio 11, 2211–5463.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>